RecruitingAdvanced Solid Tumor
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.
Sponsor: Exelixis
Where it's recruiting
California
Fountain Valley
Florida
Jacksonville · Orlando · Tampa
Minnesota
Rochester
Missouri
Kansas City
New Jersey
New Brunswick
New York
New York
Ohio
Cleveland
Oklahoma
Oklahoma City
Tennessee
Germantown · Nashville
Texas
Austin · Houston · San Antonio
Source: ClinicalTrials.gov · NCT05932862 · last updated 2025-09-05